Israeli mental health technology company GrayMatters Health (GMH) has launched Prism Suite, a set of solutions designed to support healthcare providers and improve patient outcomes in mental health care.
The suite features a depression protocol and utilises functional magnetic resonance imaging (fMRI) informed digital biomarkers to help patients manage their condition.
Go deeper with GlobalData
It builds on the company’s Prism solution for managing post-traumatic stress disorder (PTSD), which has been approved by the US Food and Drug Administration (FDA).
Prism Suite is designed to assist patients with depression by using a reward-system biomarker to regulate brain activity linked to their symptoms.
Patients engage with the programme by adopting mental strategies that animate a character in a simulation, encouraging them to undertake activities.
The suite also offers a range of tools for healthcare providers, which aim to enable the monitoring of patient progress and deliver insights into the patient experience, potentially improving engagement.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGMH highlighted that the Insights tool offers data-driven analysis and suggests discussion topics to support the process.
GrayMatters Health CEO and co-founder Oded Kraft said: “With the addition of the Depression protocol, we’re opening the door for even more patients to benefit from a personalised experience that can become a skill for daily life.
“By harnessing the power of the brain, we’re giving mental healthcare providers tools to guide their patients to meaningful, measurable progress.”
Based in Haifa, GMH develops and markets an interventional psychiatry suite of solutions that make use of digital fMRI-informed biomarkers.
The company’s PTSD treatment utilises an amygdala-based biomarker and has been used to help patients self-regulate brain activity associated with PTSD.
The treatment is available at clinics across various US states, including Florida, New York, Georgia, California, Connecticut, Illinois and Massachusetts.
The technology behind GMH’s solutions is based on EEG-fMRI-Pattern (EFP) digital biomarkers, which map high-resolution fMRI data from deep brain regions onto EEG signals.
